Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Reenaers

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Acta Gastro-Enterologica Belgica|October 10, 2023
EditorialC Reenaers, H De Schepper
Inflammatory Bowel Diseases|December 23, 2009
Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?C Reenaers, J Belaiche, E Louis
World Journal of Gastroenterology|September 24, 2008
Are we giving biologics too much time? When should we stop treatment?Edouard Louis, J Belaiche, C Reenaers
Revue Medicale De Liege|August 1, 2009
[Biologic therapies in chronic inflammatory bowel diseases]C Reenaers, E Louis, J Belaiche
Digestive Diseases (Basel, Switzerland)|September 30, 2009
Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategiesE Louis, J Belaiche, C Reenaers
Alimentary Pharmacology & Therapeutics|April 2, 2005
Infliximab and the bone in Crohn's diseaseN Franchimont, C Reenaers, E Louis
Revue Medicale De Liege|January 8, 2016
[Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases]C Van Kemseke, E Louis, C Reenaers
Journal of Crohn'S & Colitis|May 18, 2011
Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroidsC Bello, J Belaiche, E Louis, et al.
Acta Gastro-Enterologica Belgica|July 10, 2023
Clinical nutrition, skeletal muscle and liver disease: linking the dots for good managementN Lanthier, S Lefere, H De Schepper, et al.
Alimentary Pharmacology & Therapeutics|August 7, 2012
Commentary: endoscopic dilatation for stricturing Crohn's diseaseE Louis, P Gast, C Van Kemseke, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Acta Gastro-Enterologica Belgica|October 10, 2023
EditorialC Reenaers, H De Schepper
Inflammatory Bowel Diseases|December 23, 2009
Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?C Reenaers, J Belaiche, E Louis
World Journal of Gastroenterology|September 24, 2008
Are we giving biologics too much time? When should we stop treatment?Edouard Louis, J Belaiche, C Reenaers
Revue Medicale De Liege|August 1, 2009
[Biologic therapies in chronic inflammatory bowel diseases]C Reenaers, E Louis, J Belaiche
Digestive Diseases (Basel, Switzerland)|September 30, 2009
Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategiesE Louis, J Belaiche, C Reenaers
Alimentary Pharmacology & Therapeutics|April 2, 2005
Infliximab and the bone in Crohn's diseaseN Franchimont, C Reenaers, E Louis
Revue Medicale De Liege|January 8, 2016
[Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases]C Van Kemseke, E Louis, C Reenaers
Journal of Crohn'S & Colitis|May 18, 2011
Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroidsC Bello, J Belaiche, E Louis, et al.
Acta Gastro-Enterologica Belgica|July 10, 2023
Clinical nutrition, skeletal muscle and liver disease: linking the dots for good managementN Lanthier, S Lefere, H De Schepper, et al.
Alimentary Pharmacology & Therapeutics|August 7, 2012
Commentary: endoscopic dilatation for stricturing Crohn's diseaseE Louis, P Gast, C Van Kemseke, et al.
Pageof 5